2C-C

2C-C

2C-C

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

2C-C

Also known as:

  • 2-(4-Chlor-2,5-dimethoxyphenyl)ethanamin[German][ACD/IUPAC Name]
  • 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine[ACD/IUPAC Name]
  • 2-(4-Chloro-2,5-diméthoxyphényl)éthanamine[French][ACD/IUPAC Name]
  • 2,5-dimethoxy-4-chlorophenethylamine
  • 2C-C
  • 4-chloro-2,5-dimethoxyphenethylamine
  • Benzeneethanamine, 4-chloro-2,5-dimethoxy-[ACD/Index Name]
  • 2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine
  • 2-(4-Chloro-2,5-dimethoxy-phenyl)-ethylamine
  • 2,5-di-meo-4-cl-pea
  • 2,5-Dimethoxy-4-chloro-phenethylamine
  • 2,5-Dimethoxy-4-chlorophenethylamine Hydrochloride
  • 2,5-dimethoxy-4-chlorophenylethylamine
  • 2,5-DIMETHOXY-4-CHLORPHENYLETHYLAMIN
  • 2,5-Dimethoxy-4-Propylthiophen
  • 4-Chloro-2,5-dimethoxybenzeneethanamine
  • 4-Chloro-2,5-Dimethoxyphenylethylamine Hydrochloride
  • CHEMBL124733
  • phenethylamine, 4-chloro-2,5-dimethoxy-

A short-acting psychedelic research chemical of the 2c-x family. Often described as being less stimulating than the other 2c-x, and is a relatively unique psychedelic in this respect.

Summary

It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule. 2C-C was first synthesized by Alice C. Cheng and Neal Castagnoli Jr.

in 1983 as an intermediate in a study evaluating the neurotoxicity of 6-hydroxydopamine analogs. Its activity in humans was later investigated and documented by Alexander Shulgin in his book PiHKAL (“Phenethylamines I Have Known and Loved”). Many users report that the effects of 2C-C are gentler, more relaxed, and sedating than other closely related psychedelic phenethylamines such as 2C-B, 2C-I, and 2C-E.

It is one of the least potent members of the 2C-x family, with muted visual effects and a relatively unaltered headspace. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-C, and its history of human use is limited. Today, it is used for recreational and therapeutic purposes.

It is rarely sold on the streets and distributed online as a grey area research chemical.

History

Chemistry

2C-C

2C-C

2C-C contains methoxy functional groups CH3O- attached to carbons R2 and R5 as well as a chlorine atom attached to carbon R4 of the phenyl ring.

2C-C belongs to the 2C family of phenethylamines which contain methoxy groups on the 2 and 5 positions of the benzene ring.

Common Name4-chloro-2,5-dimethoxyphenethylamine
Systematic name4-chloro-2,5-dimethoxyphenethylamine
FormulaC_{10}H_{14}ClNO_{2}
SMILESCOc1cc(c(cc1Cl)OC)CCN
Std. InChiInChI=1S/C10H14ClNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3
Std. InChiKeyCGKQFIWIPSIVAS-UHFFFAOYSA-N
Avg. Mass215.6767 Da
Molecular Weight215.6767
Monoisotopic Mass215.071304 Da
Nominal Mass215
ChemSpider ID21106221

Subscribe for the latest updates

Dosing Guide

Oral
Light5-15mg
Common15-25mg
Strong25-30mg
Heavy30-40mg+

Duration

2C-C Duration Data
Onset30-120 minutes
Duration4-8 hours
After-effects1-12 hours

Interactions and Synergies

Caution

  1. Mescaline
  2. DOx
  3. NBOMes
  4. 2C-T-x
  5. 5-MeO-xxT
    • The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics
  6. Cannabis
    • Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
  7. Amphetamines
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally uneccessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  8. Cocaine
    • The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics. Combination of the stimulating effects may be uncomfortable.
  9. MAOIs
    • MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably

Dangerous

  1. Tramadol
    • Tramadol is well known to lower seizure threshold and psychedelics raise the risk of seizures.

No Synergy

  1. Caffeine
    • High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating the combination may cause some physical discomfort.
  2. Opioids

General Information

Experiences
Oral
Vaporization
Come up
Dosage
Effectseuphoria, giggling, empathy, insight, brightened color, closed/open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception of time, ego softening, nausea, sweating/chills, muscle tension, confusion, insomnia
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

2C-C’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience is the subject of ongoing scientific investigation.

Subjective Effects

Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical Effects

Psychological Effects

The head space of 2C-C is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.

Visual Effects

Enhancements

Distortions

Geometry

The visual geometry of 2C-C is more similar in appearance to that of 2C-B than that of Psilocin, 2C-E, or ayahuasca. They can be comprehensively described as unstructured in their organization, algorithmic in geometric style, intricate in complexity, large, fast and smooth in motion, colorful in scheme, glossy in color, sharp in their edges and angular in their corners.

Hallucinatory states

2C-C can produce a full range of hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. However, the dose required to reach this state is significantly higher than many related 2C-x phenethylamines. These effects include:

Auditory Effects

Sensory Effects

Transpersonal Effects

Legal Status

  • Australia: Australia has a blanket ban over all substituted phenethylamines including the entire 2C-X family.
  • Austria: 2C-C is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
  • Canada: 2C-C would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.
  • China: As of October 2015, 2C-C is a controlled substance in China.
  • Germany: 2C-C is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Japan: 2C-C is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
  • Latvia: 2C-C is a Schedule I controlled substance in Latvia.
  • Sweden: 2C-C is classified as a health hazard as of March 1, 2005 in the regulation SFS 2005:26, making it illegal to sell or possess.
  • Switzerland: 2C-C is illegal to possess, produce, or sell in Switzerland.
  • United Kingdom: 2C-C is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.
  • United States: As of July 9, 2012, 2C-C is a Schedule I substance in the United States under the Food and Drug Administration Safety and Innovation Act of 2012, making possession, distribution and manufacture illegal without a DEA license.

  • References

    1. Alexander Shulgin - PIHKAL | http://www.erowid.org/library/books_online/pihkal/pihkal033.shtml
    2. Cheng, A. C., & Castagnoli Jr, N. (1984). Synthesis and physicochemical and neurotoxicity studies of 1-(4-substituted-2, 5-dihydroxyphenyl)-2-aminoethane analogs of 6-hydroxydopamine. Journal of medicinal chemistry, 27(4), 513-520. https://doi.org/10.1021/jm00370a014
    3. 2,5-Dimethoxy-4-chlorophenethylamine (Isomer Design / PiHKAL) | http://isomerdesign.com/PiHKAL/read.php?id=22
    4. Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
    5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    6. New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New Psychoactive Substances.pdf
    7. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
    8. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
    9. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
    10. "Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
    11. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    12. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
    13. Analytical Data of Designated Substances (Shitei-Yakubutsu) Controlled by the Pharmaceutical AŠairs Law in Japan, Part I: GC-MS and LC-MS | https://www.erowid.org/references/texts/show/7395docid7635
    14. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
    15. Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050026.pdf
    16. http://web.archive.org/web/20170329020935/https://www.admin.ch/opc/de/classified-compilation/20101220/index.html
    17. United Kingdom. (1977). Misuse of Drugs Act 1971 (S.I. 1977/1243). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/1977/1243/made
    18. S. 3187: Food and Drug Administration Safety and Innovation Act, Subtitle D-Synthetic Drugs | http://www.govtrack.us/congress/bills/112/s3187/text

    Sources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.